Cargando…

Serum IL-23 significantly decreased in obese patients with psoriatic arthritis six months after a structured weight loss intervention

INTRODUCTION: Patients with psoriatic arthritis (PsA) are frequently obese. We have previously shown decreased disease activity in patients with PsA with a body mass index (BMI) ≥ 33 kg/m(2) following weight loss treatment with Very Low Energy Diet (VLED), resulting in a median weight loss of 18.6%...

Descripción completa

Detalles Bibliográficos
Autores principales:	Landgren, A. J., Jonsson, C. A., Bilberg, A., Eliasson, B., Torres, L., Dehlin, M., Jacobsson, L. T. H., Gjertsson, I., Larsson, I., Klingberg, E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373368/ https://www.ncbi.nlm.nih.gov/pubmed/37501212 http://dx.doi.org/10.1186/s13075-023-03105-8

Ejemplares similares

Cardiovascular risk factors in gout, psoriatic arthritis, rheumatoid arthritis and ankylosing spondylitis: a cross-sectional survey of patients in Western Sweden
por: Landgren, Anton Jonatan, et al.
Publicado: (2021)

Weight loss improves disease activity in patients with psoriatic arthritis and obesity: an interventional study
por: Klingberg, Eva, et al.
Publicado: (2019)

The impact of a structured weight-loss treatment on physical fitness in patients with psoriatic arthritis and obesity compared to matched controls: a prospective interventional study
por: Bilberg, Annelie, et al.
Publicado: (2022)

Weight loss is associated with sustained improvement of disease activity and cardiovascular risk factors in patients with psoriatic arthritis and obesity: a prospective intervention study with two years of follow-up
por: Klingberg, Eva, et al.
Publicado: (2020)

The role of IL‐23 and the use of IL‐23 inhibitors in psoriatic arthritis
por: Fragoulis, George E., et al.
Publicado: (2022)

Gender differences in illness perceptions and disease management in patients with gout, results from a questionnaire study in Western Sweden
por: Bergsten, Ulrika, et al.
Publicado: (2023)

Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population-based cohort study
por: Bengtsson, Karin, et al.
Publicado: (2017)

Incidence of extra-articular manifestations in ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis: results from a national register-based cohort study
por: Bengtsson, Karin, et al.
Publicado: (2020)

Investigation of association of the IL12B and IL23R genes with psoriatic arthritis
por: Filer, Charlotte, et al.
Publicado: (2008)

The IL-17/IL-23 Axis and Its Genetic Contribution to Psoriatic Arthritis
por: Vecellio, Matteo, et al.
Publicado: (2021)

Mini Review: New Treatments in Psoriatic Arthritis. Focus on the IL-23/17 Axis
por: Sakkas, Lazaros I., et al.
Publicado: (2019)

Clinical, Serological and Immunological Characteristics in Greek Patients with Psoriatic Arthritis: The Role of IL-17, IL-23, and Sclerostin
por: Venetsanopoulou, Aliki I., et al.
Publicado: (2020)

Skin expression of IL-23 drives the development of psoriasis and psoriatic arthritis in mice
por: Chen, Lili, et al.
Publicado: (2020)

The Th17/IL-23 Axis and Natural Immunity in Psoriatic Arthritis
por: Maeda, Shinji, et al.
Publicado: (2012)

IL-23 skin and joint profiling in psoriatic arthritis: novel perspectives in understanding clinical responses to IL-23 inhibitors
por: Nerviani, Alessandra, et al.
Publicado: (2021)

Replication of a distinct psoriatic arthritis risk variant at the IL23R locus
por: Budu-Aggrey, Ashley, et al.
Publicado: (2016)

Confirmation of TNIP1 and IL23A as susceptibility loci for psoriatic arthritis
por: Bowes, John, et al.
Publicado: (2011)

Considerations on inhibition of IL‐23 in psoriatic women of childbearing potential
por: Russo, Roberto, et al.
Publicado: (2021)

Choosing the Appropriate Target for the Treatment of Psoriatic Arthritis: TNFα, IL-17, IL-23 or JAK Inhibitors?
por: Gialouri, Chrysoula G., et al.
Publicado: (2022)

Methotrexate treatment in early psoriatic arthritis in comparison to rheumatoid arthritis: an observational nationwide study
por: Lindström, Ulf, et al.
Publicado: (2023)

Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review
por: Yang, Kevin, et al.
Publicado: (2020)

Impact of psoriasis disease activity and other risk factors on serum urate levels in patients with psoriasis and psoriatic arthritis—a post-hoc analysis of pooled data from three phase 3 trials with secukinumab
por: Dehlin, Mats, et al.
Publicado: (2021)

Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
por: Mease, Philip J., et al.
Publicado: (2023)

Role of the IL-23/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints
por: Boutet, Marie-Astrid, et al.
Publicado: (2018)

IL-36γ Is a Strong Inducer of IL-23 in Psoriatic Cells and Activates Angiogenesis
por: Bridgewood, Charlie, et al.
Publicado: (2018)

Incidence of and risk factors for nephrolithiasis in patients with gout and the general population, a cohort study
por: Landgren, A. J., et al.
Publicado: (2017)

Dual energy CT findings in gout with rapid kilovoltage-switching source with gemstone scintillator detector
por: Svensson, Elin, et al.
Publicado: (2020)

Evaluation of the novel ultrasound score for large joints in psoriatic arthritis and ankylosing spondylitis: six month experience in daily clinical practice
por: Schäfer, Valentin S, et al.
Publicado: (2013)

Functional role of IL-22 in psoriatic arthritis
por: Mitra, Anupam, et al.
Publicado: (2012)

Serum IL-6 and IL-23 Levels and Their Correlation with Angiogenic Cytokines and Disease Activity in Ankylosing Spondylitis, Psoriatic Arthritis, and SAPHO Syndrome
por: Przepiera-Będzak, Hanna, et al.
Publicado: (2015)

The Impact of Treatment with IL-17/IL-23 Inhibitors on Subclinical Atherosclerosis in Patients with Plaque Psoriasis and/or Psoriatic Arthritis: A Systematic Review
por: Tsiogka, Aikaterini, et al.
Publicado: (2023)

Human NCF1(90H) Variant Promotes IL-23/IL-17—Dependent Mannan-Induced Psoriasis and Psoriatic Arthritis
por: Li, Yanpeng, et al.
Publicado: (2023)

Efficacy and safety of IL-23 inhibitors in the treatment of psoriatic arthritis: a meta-analysis based on randomized controlled trials
por: Huang, Xiaojing, et al.
Publicado: (2023)

Multifaceted Analysis of IL-23A- and/or EBI3-Including Cytokines Produced by Psoriatic Keratinocytes
por: Tachibana, Kota, et al.
Publicado: (2021)

Subtype specific genetic associations for juvenile idiopathic arthritis: ERAP1 with the enthesitis related arthritis subtype and IL23R with juvenile psoriatic arthritis
por: Hinks, Anne, et al.
Publicado: (2011)

The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis
por: Blauvelt, Andrew, et al.
Publicado: (2018)

IL-20 is expressed in inflamed synovium of patients with psoriatic arthritis and rheumatoid arthritis
por: Smeets, TJM, et al.
Publicado: (2004)

From Bed to Bench and Back: TNF-α, IL-23/IL-17A, and JAK-Dependent Inflammation in the Pathogenesis of Psoriatic Synovitis
por: Silvagni, Ettore, et al.
Publicado: (2021)

Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results
por: Smolen, Josef S, et al.
Publicado: (2021)

Serum interleukin-23 levels: relation to depression, anxiety, and disease activity in psoriatic arthritis patients
por: Tabra, Samar Abdalhamed, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g38snf18otlt3j09kheaclfdcs